Investigators Pursue the Role of the Microbiome on Immunotherapy Treatment in RCC
August 1st 2023
Pedro C. Barata, MD, MSc, discusses the importance of further exploring the facets of manipulating the microbiome to augment responses with immunotherapy in RCC, as well as the promise of the bifidogenic live bacterial product, CBM588.